Increased Beta2-microglobulin in CSF of multiple sclerosis

Sir: Increased cerebrospinal fluid (CSF) levels of beta2-microglobulin (B2m) have been found in a number of primary central nervous system (CNS) diseases as well as in neurological complications of systemic malignancies, cerebral vascular lesions and CNS infection. However, there are discrepancies in the values obtained by several authors for B2m in CSF of multiple sclerosis patients.

This may be due to the fact that these studies were performed in small series of patients without taking into account whether they were in relapse or not. We felt, therefore, that the study of CSF B2m in relation to clinical activity in multiple sclerosis would be of interest.

We studied 30 patients with clinically definite multiple sclerosis. They were divided into two groups: Group A comprised 14 patients in a stable phase of the disease. Group B included 16 patients who were studied during an acute exacerbation of multiple sclerosis, their sera and CSF having been withdrawn within 3 weeks from the onset of the attack. Control CSF and serum data were obtained from 16 age-matched patients who did not show signs of organic neurological disease and whose CSF study was unremarkable. Serum and CSF B2m was measured by means of an ELISA developed in our laboratory.

No significant difference in serum B2m was found between the two multiple sclerosis groups and controls, being 1.77 ± 0.19 mg/l for group A, 1.86 ± 0.18 mg/l for group B and 1.80 ± 0.12 mg/l for controls (mean ± standard error of the mean).

CSF biochemical parameters studied are shown in the table. CSF IgG, IgG index, daily IgG synthesis and B2m were found to be significantly higher in multiple sclerosis patients in relapse. The ratio CSF/serum albumin was, however, within normal limits, thus showing a normal blood-brain barrier function.

The origin of increased CSF B2m in multiple sclerosis patients remains unclear. Higher B2m values in CSF compared with serum would indicate an intrathecal production and was found in every patient of group B. Whether B2m comes from tissue destruction or from T-cell activation is at present unknown. Nevertheless, it seems likely that CSF B2m may be an index of multiple sclerosis activity.

J. C. ALVAREZ-CERMEÑO
L. M. VILLAR
G. ROY
A. FERREIRA
A. BOOTELLO
A. GIMENO
P. GONZÁLEZ-PORQUÉ

Departments of Neurology and Immunology
Hospital Ramón Y Cajal,
Carretera de Colmenar Km 9100
Madrid 28034, Spain.

References


Accepted 7 March 1987

Late onset adrenomyeloneuropathy

Sir: Adrenomyeloneuropathy is a disorder of lipid metabolism which results in the accumulation of long chain fatty acids.1–3 The accumulation and associated dysfunction is most marked in those cells which depend highly on lipid metabolism: adrenal cortex, gonads, cerebral cortex and myelin sheaths of peripheral nerves. The condition is thus characterised by the association of Addison's disease and hypogonadism, with progressive peripheral and central neurological disease, and is usually familial. Inheritance is X-linked, and expression is usually confined to males, but several variants have been described.3 The best recognised form of this condition is that which occurs in children (adrenoleukodystrophy, Addison-Schilder's disease),4 with rapidly progressive neurological damage resulting in death within the first 15 years of life. However, a family history is not invariable, and the condition may present later.5 In their review of 303 cases, Moser et al5 described only five patients who first developed neurological symptoms after age 21 years, and none with both Addison's disease and neurological signs who presented after 37 years of age.

In 1975 a 53 year old milkman was admitted to hospital with clinical and biochemical...
Increased beta 2-microglobulin in CSF of multiple sclerosis.


J Neurol Neurosurg Psychiatry 1987 50: 1238
doi: 10.1136/jnnp.50.9.1238

Updated information and services can be found at: http://jnnp.bmj.com/content/50/9/1238.1.citation

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/